Condition: Advanced Solid Tumors · Sponsor: DualityBio Inc.
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
This description comes directly from the study's public registry record.
Ling Li · 86-21-26018730 · ling.li@dualitybiologics.com
Tiana Zhao · tiana.zhao@dualitybiologics.com
Always discuss trial participation with your own doctor first.
| Research Site 111 | Tucson, Arizona, United States | Recruiting |
| Research Site 125 | Los Angeles, California, United States | Recruiting |
| Research Site 133 | Los Angeles, California, United States | Recruiting |
| Research Site 103 | Los Angeles, California, United States | Recruiting |
| Research Site 128 | Santa Monica, California, United States | Recruiting |
| Research Site 118 | Celebration, Florida, United States | Recruiting |
| Research Site 127 | Margate, Florida, United States | Recruiting |
| Research Site 137 | Orlando, Florida, United States | Recruiting |
| Research Site 101 | Plantation, Florida, United States | Recruiting |
| Research Site 109 | Tamarac, Florida, United States | Recruiting |
| Research Site 114 | Atlanta, Georgia, United States | Recruiting |
| Research Site 139 | Atlanta, Georgia, United States | Recruiting |
+ 95 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05914116